Myasthenia gravis: A review

Autoimmune Diseases

Volumn 1, Issue 1, 2012, Pages

  Jayam Trouth, Annapurni ^a   Dabi, Alok ^a   Solieman, Noha ^a   Kurukumbi, Mohankumar ^a   Kalyanam, Janaki ^a  

^a HOWARD UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHOLINESTERASE INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; GLUCOCORTICOID; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PYRIDOSTIGMINE; RITUXIMAB; TACROLIMUS; AUTOANTIGEN; CHOLINERGIC RECEPTOR ANTIBODY; EDROPHONIUM CHLORIDE; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL CRAMP; ANOREXIA; AUTOIMMUNE DISEASE; BONE MARROW SUPPRESSION; BRADYCARDIA; BRONCHUS SECRETION; CLINICAL FEATURE; DIARRHEA; DRUG DOSE TITRATION; DRUG MECHANISM; ELECTROMYOGRAPHY; FASCICULATION; HAIR LOSS; HUMAN; IMMUNOMODULATION; LEUKOPENIA; LIVER TOXICITY; MUSCLE CRAMP; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; NAUSEA; NEPHROTOXICITY; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SALIVATION DISORDER; SIDE EFFECT; SKIN DISCOLORATION; SWEATING; THROMBOSIS; THYMECTOMY; VOMITING; BONE MARROW TRANSPLANTATION; CD4+ T LYMPHOCYTE; CRYOPRECIPITATION; CYTOKINE RELEASE; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DRUG EFFICACY; ELECTROPHYSIOLOGY; HYPOTENSION; ICE PACK TEST; IMMUNOTHERAPY; INFECTION COMPLICATION; LONG TERM CARE; NEUROMUSCULAR SYNAPSE; ONSET AGE; PARESTHESIA; PREVALENCE; REHABILITATION CARE; SALIVATION; SINGLE FIBER ELECTROMYOGRAPHY; TH1 CELL; TH2 CELL; THYMOMA; UNSPECIFIED SIDE EFFECT;

EID: 84872942199     PISSN: None     EISSN: 20900430     Source Type: Journal    
DOI: 10.1155/2012/874680     Document Type: Review

References (79)

1. Robertson N., Enumerating neurology. Brain 2000 123 4 663 664 2-s2.0-0034101032 (Pubitemid 30162715)
2. Conti-Fine B. M., Milani M., Kaminski H. J., Myasthenia gravis: past, present, and future. Journal of Clinical Investigation 2006 116 11 2843 2854 2-s2.0-33750575915 10.1172/JCI29894 (Pubitemid 44684466)
3. Grob D., Brunner N., Namba T., Pagala M., Lifetime course of myasthenia gravis. Muscle and Nerve 2008 37 2 141 149 2-s2.0-38949099991 10.1002/mus.20950 (Pubitemid 351214160)
4. Zhang X., Yang M., Xu J., Zhang M., Lang B., Wang W., Vincent A., Clinical and serological study of myasthenia gravis in Hu Bei Province, China. Journal of Neurology, Neurosurgery and Psychiatry 2007 78 4 386 390 2-s2.0-33947719422 10.1136/jnnp.2006.100545 (Pubitemid 46580547)
5. Kurukumbi M., Weir R. L., Kalyanam J., Nasim M., Jayam-Trouth A., Rare association of thymoma, myasthenia gravis and sarcoidosis: a case report. Journal of Medical Case Reports 2008 2, article no. 245 2-s2.0-49249134294 10.1186/1752-1947-2-245
6. Marsteller H. B., The first American case of myasthenia gravis. Archives of Neurology 1988 45 2 185 187 2-s2.0-0023851913
7. Wilks, Sir Samuel, Bart. In: Roll Munk's, editor. Reprinted by RCPs, 1955, P.86
8. Willis T., Pathologiae Cerebri et Nervosi Generis Specimen 1667 Oxford, UK Ja Allestry
9. Jolly F., Ueber Myasthenia Gravis Pseudoparalytica 1895 32 Berlin, Germany Klin Wochenschr
10. Hughes T., The early history of myasthenia gravis. Neuromuscular Disorders 2005 15 12 878 886 2-s2.0-28244501341 10.1016/j.nmd.2005.08.007 (Pubitemid 41713144)
11. Walker M. B., Case showing the effect of prostigmin on myasthenia gravis. Journal of the Royal Society of Medicine 1935 28 759 761
12. Pascuzzi R. M., The history of myasthenia gravis. Neurologic Clinics 1994 12 2 231 242 2-s2.0-0028434452
13. Nastuk W. L., Strauss A. J. L., Osserman K. E., Search for a neuromuscular blocking agent in the blood of patients with myasthenia gravis. The American Journal of Medicine 1959 26 3 394 409 2-s2.0-0348059900
14. Simpson J. A., Myasthenia gravis, a new hypothesis. Scott Medical 1960 5 419 436
15. Patrick J., Lindstrom J., Autoimmune response to acetylcholine receptor. Science 1973 180 4088 871 872 2-s2.0-0015935638
16. Sathasivam S., Steroids and immunosuppressant drugs in myasthenia gravis. Nature Clinical Practice Neurology 2008 4 6 317 327 2-s2.0-44949109211 10.1038/ncpneuro0810 (Pubitemid 351803614)
17. Gilhus N. E., Owe J. F., Hoff J. M., Romi F., Skele G. O., Aarli J. A., Myasthenia gravis: a review of available treatment approaches. Autoimmune Diseases 2011 10 1 6
18. Leite M. I., Waters P., Vincent A., Diagnostic use of autoantibodies in myasthenia gravis. Autoimmunity 2010 43 5-6 371 379 2-s2.0-77955897605 10.3109/08916930903541208
19. Meriggioli M. N., Sanders D. B., Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. The Lancet Neurology 2009 8 5 475 490 2-s2.0-64349115066 10.1016/S1474-4422(09)70063-8
20. Vernino S., Lennon V. A., Autoantibody profiles and neurological correlations of thymoma. Clinical Cancer Research 2004 10 21 7270 7275 2-s2.0-8444239272 10.1158/1078-0432.CCR-04-0735 (Pubitemid 39487714)
21. Leite M. I., Scröbel P., Jones M., Micklem K., Moritz R., Gold R., Niks E. H., Berrih-Aknin S., Scaravilli F., Canelhas A., Marx A., Newsom-Davis J., Willcox N., Vincent A., Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Annals of Neurology 2005 57 3 444 448 2-s2.0-20044374002 10.1002/ana.20386 (Pubitemid 40343969)
22. Vincent A., McConville J., Farrugia M. E., Newsom-Davis J., Seronegative myasthenia gravis. Seminars in Neurology 2004 24 1 125 133 2-s2.0-3042683763 10.1055/s-2004-829589 (Pubitemid 38823786)
23. Morgenthaler T. I., Brown L. R., Colby T. V., Harper C. M., Coles D. T., Thymoma. Mayo Clinic Proceedings 1993 68 11 1110 1123 2-s2.0-0027139767 (Pubitemid 24001147)
24. Romi F., Skeie G. O., Gilhus N. E., Aarli J. A., Striational antibodies in myasthenia gravis: reactivity and possible clinical significance. Archives of Neurology 2005 62 3 442 446 2-s2.0-14844334966 10.1001/archneur.62.3.442 (Pubitemid 40349480)
25. Romi F., Skeie G. O., Aarli J. A., Gilhus N. E., The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies. Archives of Neurology 2000 57 11 1596 1600 2-s2.0-0033751724
26. Jaretzki A., Barohn R. J., Ernstoff R. M., Kaminski H. J., Keesey J. C., Penn A. S., Sanders D. B., Myasthenia gravis: recommendations for clinical research standards. Annals of Thoracic Surgery 2000 70 1 327 334 2-s2.0-0034222459 10.1016/S0003-4975(00)01595-2
27. Hughes B. W., Kusner L. L., Kaminski H. J., Molecular architecture of the neuromuscular junction. Muscle and Nerve 2006 33 4 445 461 2-s2.0-33645330973 10.1002/mus.20440
28. Glass D. J., Bowen D. C., Stitt T. N., Radziejewski C., Bruno J., Ryan T. E., Gies D. R., Shah S., Mattsson K., Burden S. J., DiStefano P. S., Valenzuela D. M., DeChiara T. M., Yancopoulos G. D., Agrin acts via a MuSK receptor complex. Cell 1996 85 4 513 523 2-s2.0-15844380040 10.1016/S0092-8674(00)81252-0 (Pubitemid 26157190)
29. Morgutti M., Conti-Tronconi B. M., Sghirlanzoni A., Clementi F., Cellular immune response to acetylcholine receptor in myasthenia gravis: II. Thymectomy and corticosteroids. Neurology 1979 29 5 734 738 2-s2.0-0018411561 (Pubitemid 9135479)
30. Weiner H. L., Induction and mechanism of action of transforming growth factor- β -secreting Th3 regulatory cells. Immunological Reviews 2001 182 207 214 2-s2.0-0035186416 10.1034/j.1600-065X.2001.1820117.x (Pubitemid 33070220)
31. Christadoss P., Goluszko E., Treatment of experimental autoimmune myasthenia gravis with recombinant human tumor necrosis factor receptor Fc protein. Journal of Neuroimmunology 2002 122 1-2 186 190 2-s2.0-0036145585 10.1016/S0165-5728(01)00473-8 (Pubitemid 34075505)
32. Feferman T., Maiti P. K., Berrih-Aknin S., Bismuth J., Bidault J., Fuchs S., Souroujon M. C., Overexpression of IFN-induced protein 10 and its receptor CXCR3 in myasthenia gravis. Journal of Immunology 2005 174 9 5324 5331 2-s2.0-17944370017 (Pubitemid 40598086)
33. Shi F. D., Wang H. B., Li H., Hong S., Taniguchi M., Link H., Van Kaer L., Ljunggren H. G., Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nature Immunology 2000 1 3 245 251 2-s2.0-0034280106
34. Jander S., Stoll G., Increased serum levels of the interferon- γ -inducing cytokine interleukin-18 in myasthenia gravis. Neurology 2002 59 2 287 289 2-s2.0-0037162354 (Pubitemid 34779195)
35. Keesey J. C., Clinical evaluation and management of myasthenia gravis. Muscle and Nerve 2004 29 4 484 505 2-s2.0-1842478034 10.1002/mus.20030 (Pubitemid 38451340)
36. Vincent A., Leite M. I., Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis. Current Opinion in Neurology 2005 18 5 519 525 2-s2.0-26944499793 (Pubitemid 41476137)
37. Grob D., Arsura L., Brunner N. G., Namba T., The course of myasthenia gravis and therapies affecting outcome. Annals of the New York Academy of Sciences 1987 505 472 499 2-s2.0-0023623337
38. Pal S., Sanyal D., Jaw muscle weakness: a differential indicator of neuromuscular weakness-preliminary observations. Muscle and Nerve 2011 43 6 807 811 2-s2.0-79957959102 10.1002/mus.21990
39. Grob D., Course and management of myasthenia gravis. Journal of the American Medical Association 1953 153 6 529 532 2-s2.0-0038715033
40. Werner P., Kiechl S., Löscher W., Poewe W., Willeit J., Distal myasthenia gravis-frequency and clinical course in a large prospective series. Acta Neurologica Scandinavica 2003 108 3 209 210 2-s2.0-0041425161 10.1034/j.1600-0404.2003.00136.x (Pubitemid 37011651)
41. Pascuzzi R. M., The edrophonium test. Seminars in Neurology 2003 23 1 83 88 2-s2.0-0038115287 (Pubitemid 36857712)
42. Meriggioli M. N., Sanders D. B., Advances in the diagnosis of neuromuscular junction disorders. American Journal of Physical Medicine and Rehabilitation 2005 84 8 627 638 2-s2.0-22644432459 10.1097/01.phm.0000171169. 79816.4c (Pubitemid 41026130)
43. Sethi K. D., Rivner M. H., Swift T. R., Ice pack test for myasthenia gravis. Neurology 1987 37 8 1383 1385 2-s2.0-0023393795
44. Sanders D. B., Howard J. F., Johns T. R., Single-fiber electromyography in myasthenia gravis. Neurology 1979 29 1 68 76 2-s2.0-0018324415 (Pubitemid 9051190)
45. Oh S. J., Kim D. E., Kuruoglu R., Bradley R. J., Dwyer D., Diagnostic sensitivity of the laboratory tests in myasthenia gravis. Muscle and Nerve 1992 15 6 720 724 2-s2.0-0026680625 10.1002/mus.880150616
46. Lindstrom J. M., Seybold M. E., Lennon V. A., Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 1976 26 11 1054 1059 2-s2.0-0017171683
47. Lennon V. A., Serologic profile of myasthenia gravis and distinction from the Lambert- Eaton myasthenic syndrome. Neurology 1997 48 4 S23 S27 2-s2.0-0030907731 (Pubitemid 27174917)
48. Vincent A., Newsom-Davis J., Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. Journal of Neurology Neurosurgery and Psychiatry 1985 48 12 1246 1252 2-s2.0-0022373590 (Pubitemid 16229407)
49. Mittag T. W., Caroscio J., False-positive immunoassay for acetylcholine-receptor antibody in amyotrophic lateral sclerosis. The New England Journal of Medicine 1980 302 15 868 2-s2.0-0019320883
50. Koon H. C., Lachance D. H., Harper C. M., Lennon V. A., Frequency of seronegativity in adult-acquired generalized myasthenia gravis. Muscle and Nerve 2007 36 5 651 658 2-s2.0-35448985820 10.1002/mus.20854 (Pubitemid 47623853)
51. Cikes N., Momoi M. Y., Williams C. L., Howard F. M., Hoagland H. C., Whittingham S., Lennon V. A., Striational autoantibodies: quantitative detection by enzyme immunoassay in myasthenia gravis, thymoma, and recipients of D-penicillamine or allogeneic bone marrow. Mayo Clinic Proceedings 1988 63 5 474 481 2-s2.0-0023923563
52. Suzuki S., Satoh T., Yasuoka H., Hamaguchi Y., Tanaka K., Kawakami Y., Suzuki N., Kuwana M., Novel autoantibodies to a voltage-gated potassium channel KV1.4 in a severe form of myasthenia gravis. Journal of Neuroimmunology 2005 170 1-2 141 149 2-s2.0-28444436590 10.1016/j.jneuroim.2005.08.017 (Pubitemid 41740915)
53. Leite M. I., Jacob S., Viegas S., Cossins J., Clover L., Morgan B. P., Beeson D., Willcox N., Vincent A., IgG1 antibodies to acetylcholine receptors in seronegative myasthenia gravis. Brain 2008 131 7 1940 1952 2-s2.0-46849112624 10.1093/brain/awn092 (Pubitemid 351957451)
54. Chagnac Y., Hadani M., Goldhammer Y., Myasthenic crisis after intravenous administration of iodinated contrast agent. Neurology 1985 35 8 1219 1220 2-s2.0-0021864243 (Pubitemid 15003465)
55. Eliashiv S., Wirguin I., Brenner T., Argov Z., Aggravation of human and experimental myasthenia gravis by contrast media. Neurology 1990 40 10 1623 1625 2-s2.0-0025129784 (Pubitemid 20351364)
56. Drachman D. B., Medical progress: myasthenia gravis. The New England Journal of Medicine 1994 330 25 1797 1810 2-s2.0-0028779203 10.1056/ NEJM199406233302507
57. Bosch E. P., Subbiah B., Ross M. A., Cholinergic crisis after conventional doses of anticholinesterase medications in chronic renal failure. Muscle and Nerve 1991 14 10 1036 1037 2-s2.0-0025913999
58. Batocchi A. P., Evoli A., Schino C. D., Tonali P., Therapeutic apheresis in myasthenia gravis. Therapeutic Apheresis 2000 4 4 275 279 2-s2.0-0033851544 10.1046/j.1526-0968.2000.004004275.x
59. Gold R., Schneider-Gold C., Current and future standards in treatment of myasthenia gravis. Neurotherapeutics 2008 5 4 535 541 2-s2.0-53049086856 10.1016/j.nurt.2008.08.011
60. Samuelsson A., Towers T. L., Ravetch J. V., Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001 291 5503 484 486 2-s2.0-0035910392 10.1126/science.291.5503.484 (Pubitemid 32097072)
61. Psaridi-Linardaki L., Trakas N., Mamalaki A., Tzartos S. J., Specific immunoadsorption of the autoantibodies from myasthenic patients using the extracellular domain of the human muscle acetylcholine receptor α -subunit. Development of an antigen-specific therapeutic strategy. Journal of Neuroimmunology 2005 159 1-2 183 191 2-s2.0-12344291863 10.1016/j.jneuroim.2004. 10.002 (Pubitemid 40126191)
62. Brannagan T. H., Nagle K. J., Lange D. J., Rowland L. P., Complications of intravenous immune globulin treatment in neurologic disease. Neurology 1996 47 3 674 677 2-s2.0-0029819741 (Pubitemid 26307296)
63. Barth D., Nabavi Nouri M., Ng E., Nwe P., Bril V., Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 2011 76 23 2017 2023 2-s2.0-79958765623 10.1212/WNL.0b013e31821e5505
64. Robinson J., Eccher M., Bengier A., Liberman J., Costs and charges for plasma exchange (PLEX) versus intravenous immunoglobulin (IVIg) in the treatment of neuromuscular disease. Neurology 2012 78, article PD6.008.
65. Pascuzzi R. M., Branch Coslett H., Johns T. R., Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Annals of Neurology 1984 15 3 291 298 2-s2.0-0021329141 (Pubitemid 14164748)
66. Evoli A., Batocchi A. P., Palmisani M. T., Lo Monaco M., Tonali P., Long-term results of corticosteroid therapy in patients with myasthenia gravis. European Neurology 1992 32 1 37 43 2-s2.0-0026517755
67. Kupersmith M. J., Moster M., Bhiiiyan S., Warren F., Weinberg H., Beneficial effects of corticosteroids on ocular myasthenia gravis. Archives of Neurology 1996 53 8 802 804 2-s2.0-0029845381 (Pubitemid 26266926)
68. Bhanushali M. J., Wuu J., Benatar M., Treatment of ocular symptoms in myasthenia gravis. Neurology 2008 71 17 1335 1341 2-s2.0-55449109232 10.1212/01.wnl.0000327669.75695.38
69. Palace J., Newsom-Davis J., Lecky B., A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 1998 50 6 1778 1783 2-s2.0-0031747483 (Pubitemid 28283251)
70. Kissel J. T., Levy R. J., Mendell J. R., Griggs R. C., Azathioprine toxicity in neuromuscular disease. Neurology 1986 36 1 35 39 2-s2.0-0022630973 (Pubitemid 16186043)
71. Chaudhry V., Cornblath D. R., Griffin J. W., O'Brien R., Drachman D. B., Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001 56 1 94 96 2-s2.0-0035830428 (Pubitemid 32059658)
72. Ciafaloni E., Massey J. M., Tucker-Lipscomb B., Sanders D. B., Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology 2001 56 1 97 99 2-s2.0-0035830461 (Pubitemid 32059659)
73. Meriggioli M. N., Ciafaloni E., Al-Hayk K. A., Rowin J., Tucker-Lipscomb B., Massey J. M., Sanders D. B., Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology 2003 61 10 1438 1440 2-s2.0-0344874547 (Pubitemid 37463389)
74. Spring P. J., Spies J. M., Myasthenia gravis: options and timing of immunomodulatory treatment. BioDrugs 2001 15 3 173 183 2-s2.0-0035038625
75. Tindall R. S. A., Phillips J. T., Rollins J. A., Wells L., Hall K., A clinical therapeutic trial of cyclosporine in Myasthenia gravis. Annals of the New York Academy of Sciences 1993 681 539 551 2-s2.0-0027319951 (Pubitemid 23233874)
76. Pescovitz M. D., Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. American Journal of Transplantation 2006 6 5 859 866 2-s2.0-33745263037 10.1111/j.1600-6143.2006.01288.x (Pubitemid 44356635)
77. Tüzün E., Meriggioli M. N., Rowin J., Yang H., Christadoss P., Myasthenia gravis patients with low plasma IL-6 and IFN- γ benefit from etanercept treatment. Journal of Autoimmunity 2005 24 3 261 268 2-s2.0-17444370887 10.1016/j.jaut.2005.01.013 (Pubitemid 40545889)
78. Gronseth G. S., Barohn R. J., Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000 55 1 7 15 2-s2.0-0034641233 (Pubitemid 30460990)
79. Lavrnic D., Losen M., Vujic A., De Baets M., Hajdukovic L. J., Stojanovic V., Trikic R., Djukic P., Apostolski S., The features of myasthenia gravis with autoantibodies to MuSK. Journal of Neurology, Neurosurgery and Psychiatry 2005 76 8 1099 1102 2-s2.0-23144438560 10.1136/jnnp.2004.052415 (Pubitemid 41081284)